Loading ...

hybrid nilotinib/HPMCP HP55/Soluplus nanoparticles

Based on

1 Articles
2014 Most recent source

Composition

1

polyvinyl acetate phthalate

2138 Clear PVAP
Type Polymer
Formula
Role binder
2

nilotinib

Type Single Compound
Formula C28H22F3N7O
Role fillers
3

polyvinylcaprolactam-polyvinylacetate-polyethylene glycol

Soluplus
Type Polymer
Formula
Role fillers

Properties

General physical and chemical properties

Property Value Nanomaterial Variant Source
solubility in fasted state simulated intestinal fluid

More information/entries available to subscribers only.

Or, view sample content

Applications

Area Application Nanomaterial Variant Source
drug delivery

More information available to subscribers only.

Or, view sample content

Characterization

Biological effects

Preparation

Method 1

Type: Physical formation
Source:
Starting materials
  • polyvinyl acetate phthalate
  • nilotinib
  • polyvinylcaprolactam-polyvinylacetate-polyethylene glycol
  1. uqEXyAI5enguU
  2. ojs5jDZvgJ96mXLa065nyqgEghCzIwNMi7tO0ZZ7z1gj
  3. 4MthsX4
  4. QcDkf
Product

hybrid nilotinib/HPMCP HP55/Soluplus nanoparticles

Size: not specified

Medium/Support: none

Method 2

Type: Physical formation
Source:
Starting materials
  • hydroxypropyl methylcellulose phthalate
  • nilotinib
  • polyvinylcaprolactam-polyvinylacetate-polyethylene glycol
  1. IW8xvn1tcBbfB
  2. ykdXafSaUIgMKSl8PdzSeJuQz8od662PveuBh2tEFRXI
  3. MxM0p5O
  4. P7qUl
Product

hybrid nilotinib/HPMCP HP55/Soluplus nanoparticles

Size: not specified

Medium/Support: none

References

Full content is available to subscribers only

To view content please choose from the following:

We use cookies to improve your experience with our site. More information

Sign up for a free trial